Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In patients with chronic kidney disease (CKD), the presence of concomitant atrial fibrillation (AF) increases both the risk of thromboembolic complications and the risk of bleeding associated with the use of antithrombotic drugs. The risk of these complications is especially high in elderly and senile individuals. Currently, a number of markers of kidney damage have been identified, but the relationship between the level of their excretion in urine and the presence of bleeding in patients with CKD and AF receiving anticoagulants has not been sufficiently studied.
The aim of this study was to evaluate the possible relationship between the presence of bleeding in patients with CKD stages C3–4 and AF receiving rivaroxaban and the level of renal damage markers in urine.
The study included 266 patients aged 65 to 97 years: 140 patients with AF in combination with CKD C3a (102 women - 102 (71.8%)) and 126 patients with AF in combination with CKD C3b and 4 (90 women (71%)). Patients took rivaroxaban at a dosage of 15 mg or 20 mg once a day, depending on the glomerular filtration rate. All patients underwent a retrospective assessment of the presence of bleeding according to the HAS-BLED scale, analysis of the excretion of markers of renal injury (albumin; nephrin; neutrophil gelatinase-associated lipocalin (NGAL); kidney injury molecule-1 (KIM-1)) with urine. Additionally, an analysis of the level of markers of renal damage in the urine of 90 healthy volunteers was performed.
According to the risk of bleeding, patients were divided into 2 groups: Group 1 included patients with ≥1 point (92 patients (34.8%), average age 80.7 years). Group 2 included patients with 0 points: 174 patients (65.2%), average age 78.2 years. Of the bleeding, bruises were common in 52 patients (19%), nosebleeds were found in 22 patients (8.3%), bleeding from minor wounds was noted in 12 patients (4.3%), muscle hematomas were found in 6 patients (2.2%), bleeding from the oral cavity was found in 6 patients (2.2%), and hemorrhoidal bleeding was diagnosed in 2 patients (0.75%). The levels of NGAL and KIM-1 in urine in patients with AF and CKD in group 1 (5.6 ng/ml and 0.69 ng/ml, respectively) were statistically significantly higher compared to patients in group 2 (4.2 ng/ml (p=0.039) and 0.39 ng/ml (p=0.019).
Our study results indicate the presence of a statistically significant association between the presence of bleeding in patients with AF and CKD stages 3–4 receiving rivaroxaban with the level of tubular damage markers KIM-1 and NGAL in urine.
